Source - SMW
JP Morgan Cazenove today reaffirms its overweight investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and cut its price target to 2450p (from 2550p).

Related Charts

Hikma Pharmaceuticals (HIK)

-6.50p (-0.33%)
delayed 16:00PM